Maravai LifeSciences Holdings Past Earnings Performance
Past criteria checks 0/6
Maravai LifeSciences Holdings has been growing earnings at an average annual rate of 10%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 17.6% per year.
Key information
10.0%
Earnings growth rate
-15.9%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 17.6% |
| Return on equity | -17.5% |
| Net Margin | -41.2% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price
Oct 07Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Worth US$41.7 Based On Its Intrinsic Value?
Jul 01Maravai LifeSciences: The Future Beyond Covid Vaccines
Jun 29Need To Know: Analysts Are Much More Bullish On Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
May 13Revenue & Expenses BreakdownBeta
How Maravai LifeSciences Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 289 | -119 | 147 | 17 |
| 30 Sep 23 | 420 | 25 | 150 | 21 |
| 30 Jun 23 | 544 | 75 | 140 | 21 |
| 31 Mar 23 | 718 | 153 | 134 | 19 |
| 31 Dec 22 | 883 | 220 | 126 | 18 |
| 30 Sep 22 | 907 | 238 | 115 | 16 |
| 30 Jun 22 | 920 | 248 | 109 | 15 |
| 31 Mar 22 | 895 | 226 | 105 | 15 |
| 31 Dec 21 | 799 | 182 | 100 | 15 |
| 30 Sep 21 | 669 | 150 | 116 | 8 |
| 30 Jun 21 | 552 | 127 | 108 | 8 |
| 31 Mar 21 | 381 | 78 | 101 | 5 |
| 31 Dec 20 | 284 | 77 | 94 | 6 |
| 31 Dec 19 | 143 | -8 | 48 | 4 |
| 31 Dec 18 | 124 | -18 | 41 | 4 |
Quality Earnings: MRVI is currently unprofitable.
Growing Profit Margin: MRVI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRVI is unprofitable, but has reduced losses over the past 5 years at a rate of 10% per year.
Accelerating Growth: Unable to compare MRVI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRVI is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.6%).
Return on Equity
High ROE: MRVI has a negative Return on Equity (-17.52%), as it is currently unprofitable.